Previous Close | 19.57 |
Open | 19.98 |
Bid | 18.40 x 3100 |
Ask | 25.00 x 3200 |
Day's Range | 19.33 - 20.27 |
52 Week Range | 16.41 - 34.44 |
Volume | |
Avg. Volume | 1,085,611 |
Market Cap | 2.397B |
Beta (5Y Monthly) | 2.15 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.92 |
Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 49.90 |
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23, 2022. In addition to his current responsibilities leading the global ARIKAYCE® (amikacin liposome inhalation suspension) franchise and U.S. commercial activities, Mr. Wise will assume responsibility for all of Insmed's global commercial functions. Mr. Wi
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported data from seven presentations across three of its pillars—ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder (TPIP)—at the American Thoracic Society (ATS) 2022 International Conference.
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the H.C. Wainwright Annual Global Life Sciences Conference.